Clinical Trials
252 trialsLiposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Tianjin Medical University Cancer Institute and Hospital
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
University Hospital, Linkoeping
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
Massachusetts General Hospital
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
ANTARES
Instituto do Cancer do Estado de São Paulo
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
BACON
Second Affiliated Hospital, School of Medicine, Zhejiang University
HIPEC
Wake Forest University Health Sciences
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
The First Affiliated Hospital of Soochow University
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
Memorial Sloan Kettering Cancer Center
Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
M.D. Anderson Cancer Center
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RemeGen Co., Ltd.
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics, LLC
WoO
AGO Research GmbH
KOV-02S
National Cancer Center, Korea
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
A Trial of FANGâ„¢ Vaccine for Participants With Ovarian Cancer
Gradalis, Inc.
INSPIRE
University Health Network, Toronto
ACROPOLI
SOLTI Breast Cancer Research Group
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
CRS/HIPEC
Mercy Medical Center
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
The First Affiliated Hospital with Nanjing Medical University
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
University Medical Center Groningen
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
Zhejiang Cancer Hospital
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
Loyola University
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ludwig Institute for Cancer Research
M10MKO
The Netherlands Cancer Institute
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
ARIEL2
pharmaand GmbH
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Shandong University
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
University of Virginia
BOLD
ARCAGY/ GINECO GROUP
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Translational Research in Oncology
t
Peking Union Medical College Hospital
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center